Repare Therapeutics Inc., a clinical-stage precision oncology company, has released its financial results for the first quarter ended March 31, 2025. The company reported that its cash, cash equivalents, and marketable securities totaled $124.2 million as of March 31, 2025, a decrease from $152.8 million recorded on December 31, 2024. Despite this decline, Repare Therapeutics believes its available funds are sufficient to support its operational plans through 2027. For the first quarter of 2025, Repare recorded no revenue from collaboration agreements, contrasting with $52.4 million in revenue from the same source in the first quarter of 2024. The company's net loss increased to $30.1 million for the first quarter of 2025, compared to a net loss of $13.2 million in the same period of the previous year. In terms of expenses, research and development expenses, net of tax credits, were reported at $20.3 million for the first quarter of 2025, down from $33.0 million in the first quarter of 2024. General and administrative expenses also saw a decrease, amounting to $7.7 million compared to $8.6 million in the first quarter of the previous year. On the business front, Repare Therapeutics announced a strategic partnership with DCx Biotherapeutics, involving the out-licensing of its discovery platforms. The company is also exploring additional strategic alternatives and partnerships to advance its clinical stage pipeline and maximize shareholder value. Repare remains on track to report initial data from its LIONS and POLAR trials in the second half of the year.